159 related articles for article (PubMed ID: 35946837)
1. Physician Payments from Pharmaceutical Companies Related to Cancer Drugs.
Mitchell AP; Mishra Meza A; Trivedi NU; Bach PB; Gönen M
Oncologist; 2022 Oct; 27(10):857-863. PubMed ID: 35946837
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical industry-sponsored meals are associated with increased prescriptions and Medicare spending for dupilumab among dermatologists in the United States.
Murayama A
J Eval Clin Pract; 2024 Apr; 30(3):435-439. PubMed ID: 38149692
[TBL] [Abstract][Full Text] [Related]
3. Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology.
Duarte-García A; Crowson CS; McCoy RG; Herrin J; Lam V; Putman MS; Ross JS; Matteson EL; Shah ND
Mayo Clin Proc; 2022 Feb; 97(2):250-260. PubMed ID: 35120693
[TBL] [Abstract][Full Text] [Related]
4. The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide.
Bandari J; Ayyash OM; Turner RM; Jacobs BL; Davies BJ
Cancer; 2017 Nov; 123(22):4356-4362. PubMed ID: 28749536
[TBL] [Abstract][Full Text] [Related]
5. Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data.
Sharma M; Vadhariya A; Johnson ML; Marcum ZA; Holmes HM
BMC Health Serv Res; 2018 Apr; 18(1):236. PubMed ID: 29609611
[TBL] [Abstract][Full Text] [Related]
6. Association between industry payments and prescriptions of long-acting insulin: An observational study with propensity score matching.
Inoue K; Tsugawa Y; Mangione CM; Duru OK
PLoS Med; 2021 Jun; 18(6):e1003645. PubMed ID: 34061852
[TBL] [Abstract][Full Text] [Related]
7. Association between industry payments for opioid products and physicians' prescription of opioids: observational study with propensity-score matching.
Inoue K; Figueroa JF; Orav EJ; Tsugawa Y
J Epidemiol Community Health; 2020 Aug; 74(8):647-654. PubMed ID: 32350126
[TBL] [Abstract][Full Text] [Related]
8. Disclosure of industry payments to prescribers: industry payments might be a factor impacting generic drug prescribing.
Qian J; Hansen RA; Surry D; Howard J; Kiptanui Z; Harris I
Pharmacoepidemiol Drug Saf; 2017 Jul; 26(7):819-826. PubMed ID: 28485111
[TBL] [Abstract][Full Text] [Related]
9. Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries.
DeJong C; Aguilar T; Tseng CW; Lin GA; Boscardin WJ; Dudley RA
JAMA Intern Med; 2016 Aug; 176(8):1114-1122. PubMed ID: 27322350
[TBL] [Abstract][Full Text] [Related]
10. Association of Pharmaceutical Industry Payments to Physicians With Prescription and Medicare Expenditures for Pimavanserin.
Mehta HB; Moore TJ; Alexander GC
Psychiatr Serv; 2021 Jan; 72(1):77-80. PubMed ID: 32838675
[TBL] [Abstract][Full Text] [Related]
11. Industry Payments to Physician Specialists Who Prescribe Repository Corticotropin.
Hartung DM; Johnston K; Cohen DM; Nguyen T; Deodhar A; Bourdette DN
JAMA Netw Open; 2018 Jun; 1(2):e180482. PubMed ID: 30646086
[TBL] [Abstract][Full Text] [Related]
12. Increasing Financial Payments From Industry to Medical Oncologists in the United States, 2014-2017.
Rahman MW; Trivedi NU; Bach PB; Mitchell AP
J Natl Compr Canc Netw; 2021 Dec; 20(13):1-9. PubMed ID: 34965511
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the Strength of the Association Between Industry Payments and Prescribing Practices in Oncology.
Mitchell AP; Winn AN; Lund JL; Dusetzina SB
Oncologist; 2019 May; 24(5):632-639. PubMed ID: 30728276
[TBL] [Abstract][Full Text] [Related]
14. Associations between pharmaceutical industry payments to physicians and prescription of PARP inhibitors in the United States.
Murayama A; Marshall DC
Gynecol Oncol; 2024 Feb; 181():83-90. PubMed ID: 38147713
[TBL] [Abstract][Full Text] [Related]
15. The Association between Industry Payments and Brand-Name Prescriptions in Otolaryngologists.
Morse E; Hanna J; Mehra S
Otolaryngol Head Neck Surg; 2019 Oct; 161(4):605-612. PubMed ID: 31547772
[TBL] [Abstract][Full Text] [Related]
16. Influence of pharmaceutical marketing on Medicare prescriptions in the District of Columbia.
Wood SF; Podrasky J; McMonagle MA; Raveendran J; Bysshe T; Hogenmiller A; Fugh-Berman A
PLoS One; 2017; 12(10):e0186060. PubMed ID: 29069085
[TBL] [Abstract][Full Text] [Related]
17. Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study.
Mitchell AP; Dusetzina SB; Mishra Meza A; Trivedi NU; Bach PB; Winn AN
BMJ; 2023 Oct; 383():e075512. PubMed ID: 37879723
[TBL] [Abstract][Full Text] [Related]
18. Associations Between Industry Payments to Physicians for Antiplatelet Drugs and Utilization of Cardiac Procedures and Stents.
Yanagisawa M; Blumenthal DM; Kato H; Inoue K; Tsugawa Y
J Gen Intern Med; 2022 May; 37(7):1626-1633. PubMed ID: 34378113
[TBL] [Abstract][Full Text] [Related]
19. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.
Yeh JS; Franklin JM; Avorn J; Landon J; Kesselheim AS
JAMA Intern Med; 2016 Jun; 176(6):763-8. PubMed ID: 27159336
[TBL] [Abstract][Full Text] [Related]
20. Industry payments and physicians prescriptions: Effect of a payment restriction policy.
Ansari B
Soc Sci Med; 2021 Jun; 278():113942. PubMed ID: 33892242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
